Multiple Sclerosis News

‘Treat Me Right’ MS Society Campaign Shortlisted For Award

The Treat Me Right campaign from the MS Society in the UK was recently shortlisted for this year’s voluntary sector campaign Public Affairs Award. The campaign was launched in April 2014 during MS Week to raise awareness for the importance of providing the right treatment at the right moment…

Genzyme’s Lemtrada Approved by the FDA

Cambridge, Massachusetts based Genzyme announced Friday that the U.S. Food and Drug Administration (FDA) has approved the company’s new drug Lemtrada (alemtuzumab) for treatment of people with relapsing forms of multiple sclerosis, which includes people who experience periodic MS attacks, such as those who have relapsing-remitting MS or secondary-progressive…

Sailboat Crewed by MS Patients Circumnavigating the Globe

Oceans of Hope, a 67-foot sail yacht currently docked at North Cove Marina, New York, is on a round-the-world voyage to become the first ship to ever circumnavigate with a crew of people who have Multiple Sclerosis. The voyage, initiated by Sailing Sclerosis Foundation, set sail from Copenhagen, Denmark…

Obesity Linked To Multiple Sclerosis?

A team of researchers at the Tel Aviv University report the role of obesity as a major risk factor triggering and maintaining autoimmune diseases, such as Crohn’s Disease and multiple sclerosis. The study was published in Autoimmunity Reviews. In autoimmune diseases, the immune system reacts against the body…

Genzyme Clinical Trial for Relapsing-Remitting MS Enrolls 1st Patient

Sanofi subsidiary and rare disease treatment specialist Genzyme has just announced the successful enrollment of the first participant in their multicenter Phase II clinical trial for the company’s pipeline intravenous drug for relapsing-remitting multiple sclerosis (RRMS), vatelizumab. This novel drug is composed of humanized monoclonal antibodies that specifically…

Neuroprotective Qualities of Masitinib Drug in Stroke Encouraging For MS Indication

An encouraging experimental drug that is being developed for Multiple Sclerosis continues to show promise in being able to offer neuroprotective benefits — an effect that could slow and eventually cure MS. Masitinib, which is being developed by AB Science for numerous neurological indications, including Alzheimer’s disease, progressive multiple sclerosis, and amyotrophic…

Invisible illness video thumbnail